GlassScriptPhysician profile
Kaitlyn E Moore
NPI 1811368939
$7,769.21
in general payments reported to CMS, 2019-2025
35 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $1,137 · 2023: $5,004 · 2024: $1,088 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,375 · Food and Beverage: $2,095 · Travel and Lodging: $736 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,375.00 |
| Food and Beverage | $2,094.69 |
| Travel and Lodging | $736.10 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,239.51 | 2021-2023 | Nplate, Lumakras, Xgeva |
| Novartis Pharmaceuticals Corporation | $524.68 | 2021-2025 | Piqray, Kisqali |
| Eisai INC. | $319.09 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $292.45 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $281.16 | 2021-2022 | |
| Pfizer INC. | $264.89 | 2022-2024 | |
| Daiichi Sankyo INC. | $202.36 | 2022-2024 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $191.10 | 2022-2024 | Opdivo, Opdualag |
| Incyte Corporation | $183.93 | 2022-2024 | Jakafi, Monjuvi |
| Gilead Sciences, INC. | $160.76 | 2022-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $139.13 | 2022-2024 | Keytruda |
| Genentech USA, INC. | $109.14 | 2022-2025 | Polivy, Lunsumio, Phesgo |
| Celgene Corporation | $103.57 | 2022-2023 | Pomalyst, Reblozyl |
| Abbvie INC. | $81.47 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.58 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.27 | 2021-2023 | Libtayo |
| Sobi, INC | $57.37 | 2023-2024 | |
| Astellas Pharma US INC | $48.15 | 2021-2025 | Padcev |
| Ipsen Biopharmaceuticals, INC | $43.34 | 2022-2024 | Onivyde |
| Lilly USA, LLC | $39.63 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Rigel Pharmaceuticals, INC. | $39.20 | 2022-2024 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $38.07 | 2022 | |
| Beone Medicines USA, INC. | $34.22 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $33.21 | 2022 | |
| Myriad Genetic Laboratories, INC. | $28.46 | 2022 | |
| Mindray Ds USA, INC. | $23.63 | 2023 | Patient Monitor, Na Electrode,Indirect,International |
| Stemline Therapeutics INC. | $21.28 | 2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $20.29 | 2022 | |
| Pharmaessentia USA Corporation | $19.96 | 2024 | Besremi |
| Seagen INC. | $16.62 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.24 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.86 | 2022 | |
| Tolmar, INC. | $13.57 | 2024 | |
| Servier Pharmaceuticals LLC | $13.42 | 2023 | |
| Alexion Pharmaceuticals, INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.